When to Treat in Cold Agglutinin Disease

Prev
 1 / 21 
Next
Prev
 1 / 21 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • identify when observation is appropriate
  • recognize indications for treatment beyond hemoglobin thresholds
  • integrate symptoms, trajectory, and function into decisions
  • distinguish harmful delay from appropriate restraint
  • apply tempo-based clinical judgment

Which principle best guides treatment decisions in CAD?

a
Treat when hemoglobin falls below a fixed value
No single hemoglobin threshold dictates therapy.
b
Treat when laboratory abnormalities appear
Numbers alone are insufficient.
c
Treat when disease causes meaningful clinical harm
Treatment is justified when disease meaningfully harms the patient.
d
Treat all patients with detectable cold agglutinins
Many patients do not require therapy.

Which patient is most appropriate for observation?

a
Hb 9 g/dL, stable for 6 months, minimal symptoms
Stable disease with low impact may be monitored.
b
Hb 11 g/dL with recurrent exacerbations
Recurrent exacerbations suggest active disease.
c
Hb 10 g/dL with transfusion requirement
Transfusion need indicates significant burden.
d
Hb 12 g/dL with progressive fatigue
Symptoms may justify treatment even with near-normal Hb.

Which finding most strongly supports starting therapy?

a
Single low hemoglobin value
Snapshot values are insufficient.
b
High antibody titer alone
Titers do not dictate treatment.
c
Progressive decline in hemoglobin over time
Trajectory often matters as much as absolute severity.
d
Cold exposure history
Exposure alone does not determine severity.

Why is hemoglobin an unreliable sole trigger for treatment?

a
It fluctuates randomly
Variation is not the main issue.
b
Patients may physiologically adapt to chronic anemia
Physiologic adaptation may allow tolerance of chronic anemia.
c
It is unrelated to disease severity
Hemoglobin is relevant but incomplete.
d
It is technically inaccurate
Measurement is generally reliable.

Which statement about plasmapheresis in CAD is most accurate?

a
Immediate treatment — hemoglobin is dangerously low
Absolute values alone do not mandate treatment.
b
Transfusion to normalize hemoglobin
Treating numbers without symptoms is inappropriate.
c
Continued observation with structured monitoring
Stability, absence of symptoms, and preserved function support observation.
d
Urgent clone-directed therapy
Urgency is not determined by hemoglobin alone.

A colleague recommends starting therapy in a stable mildly anemic patient “before things get worse.” Which response best reflects expert reasoning?

a
Early intervention is always preferable
No evidence supports universal preemptive treatment.
b
Treatment should begin before symptoms appear
Symptoms and trajectory matter.
c
Therapy should start once anemia is detected
Detection alone is insufficient.
d
Observation with structured monitoring is a deliberate strategy, not delay
Structured observation distinguishes restraint from neglect.

Which situation most clearly warrants accelerated treatment tempo?

a
Stable anemia for years
Stable disease allows time.
b
Mild symptoms with preserved function
Low impact does not require urgency.
c
Acute hemolytic exacerbation
Acute worsening justifies faster action.
d
Isolated positive titer
Laboratory findings alone do not determine urgency.

Why is response to cold avoidance unreliable as a way to determine whether pharmacologic therapy is needed?

a
Cold avoidance eliminates hemolysis in all patients
It does not eliminate disease.
b
Persistent hemolysis may occur despite precautions because of underlying biology
Pathogenic clonal disease may persist despite avoidance, reflecting biology rather than adherence.
c
Cold avoidance cures the disorder
Avoidance does not alter the clone.
d
Cold exposure is unrelated to disease activity
Temperature can trigger symptoms.

Which cognitive error most commonly delays appropriate treatment?

a
Underestimating disease impact
Mild-appearing labs can conceal meaningful burden.
b
Overestimating symptoms
The opposite error is more typical.
c
Overvaluing trajectory
Trajectory is essential.
d
Ignoring hemoglobin entirely
Hemoglobin contributes to decisions but is not the only domain.

Which principle best captures treatment timing?

a
Treat immediately once CAD is diagnosed
Many patients can be observed.
b
Treat only when severe anemia develops
Waiting for severity may cause harm.
c
Delay treatment until labs worsen
Waiting for numbers alone is unsafe.
d
Match treatment intensity to disease behavior
Therapy should match biology, symptoms, and trajectory.

A patient with Hb 9.8 g/dL reports disabling fatigue and reduced daily function. Which interpretation is most appropriate?

a
Hemoglobin is too high to treat
No fixed threshold exists.
b
Symptoms likely unrelated
Symptoms may reflect disease.
c
Functional impact may justify treatment (after excluding alternate causes)
Functional impairment is a legitimate trigger for therapy.
d
Observation is mandatory
Observation is not obligatory.

Which pattern should prompt reassessment of an observation strategy?

a
Stable labs for 1 year
Stability supports observation.
b
Mild anemia without symptoms
May be monitored.
c
Gradual hemoglobin decline over months
Worsening trajectory signals changing disease biology.
d
Positive titer with no symptoms
Titers alone do not guide decisions.

A patient stable for 3 years shows hemoglobin decline from 10.2 → 8.5 g/dL over two months with new fatigue. What is the most important signal?

a
Absolute hemoglobin value
Snapshot values are incomplete.
b
Rate and direction of change
Tempo of change is often the strongest clinical signal.
c
Duration of prior stability
Prior stability does not determine current risk.
d
Presence of fatigue alone
Symptoms matter but trajectory is more informative here.

Sort each scenario according to the first appropriate clinical response, not the final decision.

New transfusion dependence
Asymptomatic mild anemia
Rapid Hb decline
Stable Hb, minimal symptom
Recurrent exacerbations
Observation appropriate
Treatment indicated
Reassessment needed

Match each concept to its implication:

Trajectory
Symptoms
Identical hemoglobin values
Independent treatment trigger
Often more informative than snapshot
Different decisions possible
Correct! Sorry, Incorrect.

Closing Note

Deciding when to treat in cold agglutinin disease is not about thresholds.

It is about recognizing harm.

The clinician’s task is not to normalize laboratory values, but to recognize when disease meaningfully interferes with a patient’s life, physiology, or stability. Treatment timing is therefore not dictated by numbers. It is determined by judgment.

Prev
 1 / 21 
Next